Table 4 Subgroup analyses of overall survival
Subgroup | No. of studies | HR (95% CI) | P | Heterogeneity | Model | |
|---|---|---|---|---|---|---|
I2 (%) | Ph | |||||
Cancer type | ||||||
RCC | 3 | 3.05 (2.07–4.50) | < 0.001 | 0.0 | 0.933 | Fixed |
UC | 6 | 1.58 (1.32–1.89) | < 0.001 | 7.3 | 0.370 | Fixed |
Cancer stage | ||||||
Non-metastatic | 6 | 2.14 (1.45–3.15) | < 0.001 | 58.1 | 0.036 | Random |
Metastatic | 1 | 1.57 (1.06–2.31) | 0.023 | – | – | – |
Mixed | 2 | 1.69 (1.29–2.22) | < 0.001 | 42.2 | 0.189 | Fixed |
Treatment | ||||||
Surgery | 8 | 2.02 (1.53–2.68) | < 0.001 | 50.6 | 0.048 | Random |
Mixed | 1 | 1.57 (1.06–2.31) | 0.023 | – | – | – |
Sample size | ||||||
> 400 | 4 | 1.73 (1.40–2.12) | < 0.001 | 47.9 | 0.124 | Fixed |
< 400 | 5 | 2.02 (1.33–3.07) | 0.001 | 53.9 | 0.070 | Random |
Cuf-off | ||||||
3 | 4 | 2.31 (1.44–3.72) | 0.001 | 54.0 | 0.089 | Random |
≤ 2 | 5 | 1.68 (1.38–2.05) | < 0.001 | 45.0 | 0.122 | Fixed |
Population | ||||||
Asian | 8 | 1.73 (1.46–2.04) | < 0.001 | 44.9 | 0.08 | Fixed |
African | 1 | 2.81 (1.44–5.50) | 0.003 | – | – | – |